Pluristem Therapeutics (PSTI) Leaps on FDA Designation


27% profits every 20 days?

This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.


Pluristem Therapeutics Inc. (NASDAQ: PSTI) shares rose 14.1% to $1.13 after the company reported that the U.S. FDA has granted Orphan Drug Designation to Pluristem's PLX-PAD cells. Share volume was 446.000, compared to an all-day average of 33,000

27% profits every 20 days?

This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!